

Different modes of SecY–SecA interactions revealed by site-directed *in vivo* photo-cross-linking

Hiroyuki Mori and Koreaki Ito*

Institute for Virus Research, Kyoto University, Kyoto 606-8507, Japan

Edited by Tom A. Rapoport, Harvard Medical School, Boston, MA, and approved September 7, 2006 (received for review July 27, 2006)

While the SecA ATPase drives protein translocation across the bacterial cytoplasmic membrane by interacting with the SecYEG translocon, molecular details of SecA–SecY interaction remain poorly understood. Here, we studied SecY–SecA interaction by using an *in vivo* site-directed cross-linking technique developed by Schultz and coworkers [Chin, J. W., Martin, A. B., King, D. S., Wang, L., Schultz, P. G. (2002) *Proc. Natl. Acad. Sci. USA* 99:11020–11024 and Chin, J. W., Schultz, P. G. (2002) *ChemBioChem* 3:1135–1137]. Benzoyl-phenylalanine introduced into specific SecY positions at the second, fourth, fifth, and sixth cytoplasmic domains allowed UV cross-linking with SecA. Cross-linked products exhibited two distinct electrophoretic mobilities. SecA cross-linking at the most C-terminal cytoplasmic region (C6) was specifically enhanced in the presence of NaN₃, which arrests the ATPase cycle, and this enhancement was canceled by *cis* placement of some secY mutations that affect SecY–SecA cooperation. *In vitro* experiments showed directly that SecA approaches C6 when it is engaging in ATP-dependent preprotein translocation. On the basis of these findings, we propose that the C6 tail of SecY interacts with the working form of SecA, whereas C4–C5 loops may offer constitutive SecA-binding sites.

protein translocation | translocon

Sec-mediated protein translocation takes place via the evolutionarily conserved translocon, SecYEG in prokaryotes and Sec61 $\alpha\beta\gamma$ in eukaryotes (1). These channel-like transmembrane complexes (2) can cooperate with different cytosolic components. In bacteria, SecYEG participates in both the SRP- and ribosome-dependent cotranslational integration of membrane proteins and the SecB- and SecA-dependent posttranslational translocation of periplasmic and outer membrane proteins (3, 4). The crucial factor for the latter process is the SecA ATPase that drives preprotein movement into and across the translocon (5). In doing so, a SecA–preprotein complex must interact specifically with SecYEG (6), leading to its large conformational changes coupled with the ATP hydrolysis cycles (7).

SecY has 10 transmembrane regions (TM1–TM10, numbered from amino to carboxyl termini), six cytoplasmic regions (C1–C6), and five periplasmic regions (P1–P5) (ref. 8; see also Fig. 14), with its N-terminal (TM1–TM5) and C-terminal (TM6–TM10) halves arranged pseudosymmetrically in three dimensions (2). It forms a heterotrimeric complex, having an hourglass-shaped narrow pathway for polypeptide transit in the SecY portion. Although a single unit of the trimer is thought to serve as a translocation channel (2, 9), exact oligomeric state of the heterotrimer has not been established (10–14).

SecA binds with high affinity to membranes containing SecYEG (15), which stimulates the SecA ATPase activity (16). Although cross-linking experiments using formaldehyde treatment of the cell detected direct cross-linked products between SecA and SecY (17), SecA-binding sites on the SecY molecule have not been identified. SecA-binding assays using truncated SecY polypeptides fixed onto membrane filters suggested that a N-terminal region of SecY binds SecA (18). However, it is difficult to evaluate the significance of the results obtained in such artificial experimental settings. In the structure of the

translocon, the C-terminal half of SecY contains relatively large C4–C6 protrusions, which were postulated to act as a platform for binding of cytosolic factors, such as the ribosome and SecA (2).

Although site-directed chemical cross-linking approaches are effective for studying arrangements of subunits, such as SecY–SecG and SecY–SecE, of the constitutively formed SecYEG complex (19–21), they may not be effective enough to reveal transient association of SecYEG with SecA that should undergo dynamic conformational changes during the functioning. Our genetic and biochemical studies revealed that the C5 and C6 regions of SecY are indeed important for supporting the translocase function of SecA (6, 22–25). Whereas mutations such as secY39 (Arg-357–His in C5) (24, 26) and secY205 (Tyr-429–Asp in C6) compromise the functioning of SecA, including its “insertion” ability, compensatory or up-regulating alterations in SecA suppress such defects (6, 27). Other mutations in secY, known as *pri* (28) and “super active” (29) alleles, apparently allow more effective utilization of SecA.

In this work, we attempted to study *in vivo* interaction between SecY and SecA, using the innovative technique developed by Schultz and colleagues (30, 31) that allows site-directed *in vivo* cross-linking. In this experimental system, an *amber* suppressor tRNA and a tyrosyl-tRNA synthetase from *Methanococcus jannaschii* are mutated to allow the charging of the tRNA with *p*-benzoyl-phenylalanine (pBPA), a photo-reactive phenylalanine derivative (32). The benzophenone group of pBPA reacts with a nearby C–H bond upon excitation at 350–365 nm, and its positioning in the primary target protein can be manipulated by introduction of an *amber* (TAG) codon. Thus, we carried out *in vivo* cross-linking using SecY mutants having *amber* codons in the cytosolic regions. UV irradiation of cells cultivated in the presence of pBPA revealed marked cross-linking with SecA at specific SecY positions. We thus identified SecY residues that are adjacent to SecA *in vivo*. Among them, residues at C6 were found to be approached by a working form of SecA as it is driving preprotein translocation.

Results

The Feasibility of Using Site-Directed *In Vivo* Cross-Linking with SecY.

We tested the technique of Chin *et al.* (30) at three positions of SecY previously shown to be near neighbors of SecG or SecE (19, 20). We introduced two plasmids into *Escherichia coli* cells, one encoding the *amber* suppressor tRNA and the engineered tyrosyl-tRNA synthetase (30) and the other encoding a SecY–His₆–Myc with an *amber* mutation at positions 117, 179, or 354. As presented in *Supporting Text*, which is published as supporting

Author contributions: H.M. and K.I. designed research; H.M. performed research; H.M. and K.I. analyzed data; and H.M. and K.I. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS direct submission.

Freely available online through the PNAS open access option.

Abbreviations: pBPA, *p*-benzoyl-phenylalanine; IMV, inverted membrane vesicle.

*To whom correspondence should be addressed. E-mail: kito@virus.kyoto-u.ac.jp.

© 2006 by The National Academy of Sciences of the USA




Fig. 1. Target SecY residues and SecY-SecA cross-linking conditions. (A) The amino acid residues of SecY are displayed to indicate cytoplasmic (C1-C6), transmembrane, and periplasmic regions (8). The residues individually mutated to *amber* in this study are indicated by solid circles. The SecY alterations that were introduced additionally into some of the *amber* mutants are shown by arrows with allele names. (B-D) Demonstration of *in vivo* photo-cross-linking between SecY and SecA. Cells expressing the *amber* 434 mutant of SecY-His₆-Myc (lanes 1-8) or WT SecY-His₆-Myc (lanes 9 and 10) were grown in the presence of pBPA, treated with 0.08% NaN₃ for 5 min, and UV-irradiated for the indicated periods of time (min). Membrane proteins were separated by 7.5% SDS/PAGE and analyzed by anti-SecA (B) and anti-Myc (C) immunoblotting. The cross-linked proportions (%) in the membrane-associated SecA molecules (B) are depicted graphically in D.

information on the PNAS web site, *amber* fragments of SecY were detected in the absence of pBPA, whereas growth in the presence of pBPA led to the production of the full-size SecY-

His₆-Myc (Fig. 7, which is published as supporting information on the PNAS web site). The SecYEG-His₆-Myc (*amber*) plasmids were also shown to pBPA-dependently complement the growth defect caused by the chromosomal *secY39*(Cs) mutation (data not shown). Thus, introduction of pBPA, at least into the positions examined above, does not interfere with the functioning of SecY. UV irradiation of the pBPA-grown cells led to the formation of a SecY-SecG or a SecY-SecE cross-linked product as expected (Fig. 7). Thus, the *in vivo* cross-linking approach can effectively address the subunit interactions of the SecYEG complex.

Cross-Linking Between SecY and SecA. To survey cytosolic residues of SecY for their proximity to other proteins, we constructed a total of 53 *amber* mutants of SecY-His₆-Myc, as shown in Fig. 1A. UV irradiation of cells grown in the presence of pBPA, isolation of membranes, and their electrophoretic/immunoblotting analysis allowed us to identify a number of SecY positions at which it was cross-linkable with SecA (Fig. 2). For instance, UV irradiation of cells expressing SecY-His₆-Myc *amber*-434 yielded a band above normal SecA and reacting with both anti-SecA (Fig. 1B) and anti-Myc (Fig. 1C). The appearance of this SecY-SecA cross-linked product was irradiation-dependent, reaching the maximum ($\approx 25\%$ conversion of the membrane-associated SecA molecules) in ≈ 3 min under the experimental conditions used (Fig. 1D). This irradiation time was used in all of the photo-cross-linking experiments in this study.

All 53 *amber* constructs were tested for *in vivo* photo-cross-linking. Immunoblotting with anti-SecA (Fig. 2) showed that the following SecY positions yielded a significant cross-linking with SecA: positions 109 and 111 in C2 (Fig. 2B); positions 248, 262, and 264 in C4 (Fig. 2D); positions 347 and 358 in C5 (Fig. 2E); and positions 433, 434, 435, 436, 437, and 438 in C6 (Fig. 2F). Interestingly, two distinct electrophoretic mobilities were noted. The products mediated by the C2 or the C5 residues migrated slower than those mediated by the residues in C4 or C6.

NaN₃ Enhances SecY Cross-Linking with SecA at C6. To correlate the degree of cross-linking to specific functional state of SecY/SecA, we carried out the photo-cross-linking both with and without prior treatment of cells with NaN₃, which is known to arrest the ATPase cycle of SecA (33) and to stabilize the "membrane-inserted" state of SecA by retarding the "de-insertion" step (34). In fact, the results presented in Fig. 2 had been obtained after NaN₃ treatment. All of the positions were tested for the effect




Fig. 2. Survey of the SecY cytoplasmic residues for pBPA-mediated cross-linking with SecA. Cells expressing SecY-His₆-Myc derivatives having pBPA at the indicated *amber* positions were treated with 0.08% NaN₃ for 5 min and UV-irradiated for 3 min, as indicated. Membrane fractions were analyzed by 7.5% SDS/PAGE and anti-SecA immunoblotting. Cross-linked products are indicated by * for lower mobility product and ** for higher mobility product.




Fig. 5. *In vitro* photo-cross-linking at SecY positions 347 and 434. (A) Effects of concurrent translocation. IMVs (30 ng protein/ μ l) containing pBPA at indicated positions of SecY were mixed with SecA (5 ng/ μ l) and with ATP (5 mM) and proOmpA (1 ng/ μ l) as indicated. Samples were incubated at 37°C for 20 min, UV-irradiated for 3 min, and analyzed by anti-SecA immunoblotting. (B) SecY C5 domain interacts with the N-terminal 2/3 of SecA. IMVs (30 ng protein/ μ l) containing pBPA at SecY positions 347 (lanes 1–4) or 434 (lanes 5–8) were mixed with 5 ng/ μ l of either SecA or its N68 fragment and incubated at 37°C for 5 min, followed by UV irradiation for 3 min as indicated. Membranes were analyzed by anti-SecA (Upper) and anti-SecY (Lower) immunoblotting. A new cross-linked product observed specifically with the combination of the *amber-347* IMVs and N68 is indicated by the solid circle.

in the presence of ATP and proOmpA (data not shown). These results suggest that N68 that includes the ATPase domains of SecA is close to the C5 domain of SecY.

Discussion

Although Chin and Shultz (31) reported that their experimental system is effective in executing site-directed protein cross-linking *in vivo*, we have reported here its full-scale application to the residue-level *in vivo* analyses of protein–protein interactions in a biologically important molecular assembly. This approach is especially useful for dissecting the SecA–SecYEG interaction that changes during the course of protein translocation facilitation. We identified residues in cytoplasmic domains of SecY that are close enough to SecA to allow efficient cross-linking. Not all of the cytoplasmic domains contained such a residue. Thus, we failed to observe any SecA cross-linking at C1, at which cross-linking with SecY itself was observed (H.M., unpublished results) or at C3, at which cross-linking with SecG was observed.

Involvement of these SecY regions in self-dimerization and SecG binding, respectively, is consistent with previous reports (19, 21).

The remaining cytoplasmic domains, C2, C4, C5, and C6, all contained residues cross-linkable with SecA. On the 3D structure model of SecY (2, 38), the side chains of Ser-111 (C2), Tyr-248 (C4), Ser-262 (C4), Lys-347 (C5), and Lys-434 (C6) all are located at or near the tips of the cytoplasmic protrusions (Fig. 6A). It is also notable that the majority of the residues that are in-close neighbors of SecA are in the C-terminal half of the pseudosymmetry units (Fig. 6A), as discussed by Van den Berg *et al.* (2), and are consistent with the implications from our genetic studies (6, 22, 24, 25). Ser-111 in the N-terminal half is in the proximity of both SecA and SecG (19), in line with the SecA-related functional roles assigned for SecG (39, 40). After completion of this work, van der Sluis *et al.* (41) identified two SecY regions as potential interaction sites with SecA, C5 identified by chemical cross-linking and the cytoplasmic end of TM4 identified by a peptide array binding assay. Whereas the former site agrees with our conclusion, the significance of the latter site should be validated by experiments using native materials. The *in vivo* approaches we used in this study will be useful for the analysis of SecY–SecA interactions involving transmembrane regions of SecY.

Treatment of cells with NaN_3 resulted in specific enhancement of SecA cross-linking with C6 residues, but not at other cytoplasmic domains of SecY. The NaN_3 response was lost by an additional mutation, either *secY205* or *prlA3* of *secY*. Previous studies suggest that the *secY205* mutation impairs the ability of SecY to support SecA functions, including its “insertion” (6), whereas the *prlA* mutations up-regulates the SecA-activating function of SecY (28, 42). Although the absolute levels of SecA cross-linking with these mutant forms of SecY should be compared by more quantitative experiments, we assume that these mutations abolish the NaN_3 effect on the cross-linking through different mechanisms. Our *in vitro* results lend direct support to our conclusion that C6 interacts preferentially with SecA that is actively delivering a preprotein into the translocon.

We propose that the C4–C5 region provides relatively constitutive binding sites for SecA. Our results using the C-terminally truncated SecA variant (N68) indicate that C5 is close to the N-terminal 2/3 of SecA. The ability of the N-terminal region of SecA to bind to SecYEG is consistent with a previous report (43). If the different SDS/PAGE mobilities of the cross-linked products reflect the positions of SecA responsible for the cross-linking, it seems possible that the slower migrating product is mediated by the N-terminal region of SecA, and the faster migrating product is formed at the C-terminal region of SecA (Fig. 6B). This possibility, along with more precise determination of the partner residues in SecA, remains left for further experimental analyses. At any rate, the present results reveal at least three different modes of SecA–SecY interactions: (i) a dynamic and function-related interaction involving C6 of SecY and giving the faster-migrating product, (ii) a static interaction involving C5 of SecY and the N-terminal part of SecA and giving the slower-migrating product, and (iii) a static interaction involving C4 and giving the faster-migrating product (Fig. 6B). It is possible that the interaction involving C2 is similar to the second interaction above.

We believe that the second interaction that occurs between the ATPase region of SecA and the C5 loop of SecY leads to the activation of SecA ATPase. A C5 residue Arg-357 was shown previously to be of particular importance for the SecY function in activating SecA (3, 24). On the other hand, the first interaction involving C6 is related to the event, in which SecA actively drives translocation. These interpretations are consistent with our genetic observation that ATPase activation and preprotein translocation are separable (58). The fact that a number of the C6 residues can be cross-linked to SecA might imply that SecA

1. Osborne AR, Rapoport TA, van den Berg B (2005) *Annu Rev Cell Dev Biol* 21:529–550.
2. Van den Berg B, Clemons WM, Jr, Collinson I, Modis Y, Hartmann E, Harrison SC, Rapoport TA (2004) *Nature* 427:36–44.
3. Mori H, Ito K (2001) *Trends Microbiol* 9:494–500.
4. Veenendaal AK, van der Does C, Driessen AJ (2004) *Biochim Biophys Acta* 1694:81–95.
5. Vrontou E, Economou A (2004) *Biochim Biophys Acta* 1694:67–80.
6. Matsumoto G, Yoshihisa T, Ito K (1997) *EMBO J* 16:6384–6393.
7. Economou A, Wickner W (1994) *Cell* 78:835–843.
8. Akiyama Y, Ito K (1987) *EMBO J* 6:3465–3470.
9. Cannon KS, Or E, Clemons WM, Jr, Shibata Y, Rapoport TA (2005) *J Cell Biol* 169:219–225.
10. Manting EH, van Der Does C, Remigy H, Engel A, Driessen AJ (2000) *EMBO J* 19:852–861.
11. Breyton C, Haase W, Rapoport TA, Kuhlbrandt W, Collinson I (2002) *Nature* 418:662–665.
12. Mori H, Tsukazaki T, Masui R, Kuramitsu S, Yokoyama S, Johnson AE, Kimura Y, Akiyama Y, Ito K (2003) *J Biol Chem* 278:14257–14264.
13. Duong F (2003) *EMBO J* 22:4375–4384.
14. Mitra K, Schaffitzel C, Shaikh T, Tama F, Jenni S, Brooks CL, 3rd, Ban N, Frank J (2005) *Nature* 438:318–324.
15. Douville K, Price A, Eichler J, Economou A, Wickner W (1995) *J Biol Chem* 270:20106–20111.
16. Lill R, Cunningham K, Brundage LA, Ito K, Oliver D, Wickner W (1989) *EMBO J* 8:961–966.
17. Manting EH, van der Does C, Driessen AJ (1997) *J Bacteriol* 179:5699–5704.
18. Snyders S, Ramamurthy V, Oliver D (1997) *J Biol Chem* 272:11302–11306.
19. Satoh Y, Matsumoto G, Mori H, Ito K (2003) *Biochemistry* 42:7434–7441.
20. Satoh Y, Mori H, Ito K (2003) *Biochemistry* 42:7442–7447.
21. van der Sluis EO, Nouwen N, Driessen AJ (2002) *FEBS Lett* 527:159–165.
22. Taura T, Yoshihisa T, Ito K (1997) *Biochimie* 79:517–521.
23. Mori H, Ito K (2001) *Proc Natl Acad Sci USA* 98:5128–5133.
24. Mori H, Ito K (2003) *J Bacteriol* 185:405–412.
25. Chiba K, Mori H, Ito K (2002) *J Bacteriol* 184:2243–2250.
26. Baba T, Jacq A, Brickman E, Beckwith J, Taura T, Ueguchi C, Akiyama Y, Ito K (1990) *J Bacteriol* 172:7005–7010.
27. Matsumoto G, Nakatogawa H, Mori H, Ito K (2000) *Genes Cells* 5:991–999.
28. van der Wolk JP, Fekkes P, Boorsma A, Huie JL, Silhavy TJ, Driessen AJ (1998) *EMBO J* 17:3631–3639.
29. Mori H, Shimizu Y, Ito K (2002) *J Biol Chem* 277:48550–48557.
30. Chin JW, Martin AB, King DS, Wang L, Schultz PG (2002) *Proc Natl Acad Sci USA* 99:11020–11024.
31. Chin JW, Schultz PG (2002) *ChemBioChem* 3:1135–1137.
32. Dorman G, Prestwich GD (1994) *Biochemistry* 33:5661–5673.
33. Oliver DB, Cabelli RJ, Dolan KM, Jarosik GP (1990) *Proc Natl Acad Sci USA* 87:8227–8231.
34. Eichler J, Rinard K, Wickner W (1998) *J Biol Chem* 273:21675–21681.
35. Osborne RS, Silhavy TJ (1993) *EMBO J* 12:3391–3398.
36. Taura T, Akiyama Y, Ito K (1994) *Mol Gen Genet* 243:261–269.
37. Matsumoto G, Homma T, Mori H, Ito K (2000) *J Bacteriol* 182:3377–3382.
38. Mori H, Shimokawa N, Satoh Y, Ito K (2004) *J Bacteriol* 186:3960–3969.
39. Matsumoto G, Mori H, Ito K (1998) *Proc Natl Acad Sci USA* 95:13567–13572.
40. Suzuki H, Nishiyama K, Tokuda H (1998) *Mol Microbiol* 29:331–341.
41. van der Sluis EO, Nouwen N, Koch J, de Keyzer J, van der Does C, Tampe R, Driessen AJ (2006) *J Mol Biol* 361:839–849.
42. Duong F, Wickner W (1999) *EMBO J* 18:3263–3270.
43. Dapic V, Oliver D (2000) *J Biol Chem* 275:25000–25007.
44. Natale P, den Blaauwen T, van der Does C, Driessen AJ (2005) *Biochemistry* 44:6424–6432.
45. Or E, Boyd D, Gon S, Beckwith J, Rapoport T (2005) *J Biol Chem* 280:9097–9105.
46. de Keyzer J, van der Sluis EO, Spelbrink RE, Nijstad N, de Kruijff B, Nouwen N, van der Does C, Driessen AJ (2005) *J Biol Chem* 280:35255–35260.
47. Jilaveanu LB, Oliver D (2006) *J Bacteriol* 188:335–338.
48. Jilaveanu LB, Zito CR, Oliver D (2005) *Proc Natl Acad Sci USA* 102:7511–7516.
49. Silhavy TJ, Berman ML, Enquist LW (1984) *Experiments with Gene Fusions* (Cold Spring Harbor Lab Press, Cold Spring Harbor, NY).
50. Akiyama Y, Ito K (1990) *Biochem Biophys Res Commun* 167:711–715.
51. Yanisch-Perron C, Vieira J, Messing J (1985) *Gene* 33:103–119.
52. Farrell IS, Toroney R, Hazen JL, Mehl RA, Chin JW (2005) *Nat Methods* 2:377–384.
53. Prentki P, Krusch HM (1984) *Gene* 29:303–313.
54. Mori H, Akiyama Y, Ito K (2003) *J Bacteriol* 185:948–956.
55. Ito K, Cerretti DP, Nashimoto H, Nomura M (1984) *EMBO J* 3:2319–2324.
56. Shimoike T, Akiyama Y, Baba T, Taura T, Ito K (1992) *Mol Microbiol* 6:1205–1210.
57. Nakatogawa H, Mori H, Ito K (2000) *J Biol Chem* 275:33209–33212.
58. Mori H, Ito K (2006) *J Biol Chem*, in press.